Literature DB >> 29117642

Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?

Claudia G S Osorio-de-Castro1, Thiago B Azeredo2, Vera L E Pepe3, Luciane C Lopes4, Sueli Yamauti4, Brian Godman5,6, Lars L Gustafsson5.   

Abstract

Brazil has had a National Essential Medicines List (EML) since 1964. From 2000 to 2010, five consecutive evidence-based editions were produced, building on the essential medicine concept. In 2012, the government changed course to establish a new paradigm, introducing adoption of new medicines as the main aim within the recommendation process. The objective of the article was to report efforts to develop Brazil's national EML, policy changes from 2000 to 2014, discussing results, challenges and perspectives. Brazilian EML history and development process were collected from legislation, minutes, reports and legal ordinances, from 2000 to 2014. The Brazilian EML and the WHO Model Lists were compared using the Anatomical Therapeutic Chemical system. Overlap between lists was verified, and linear trends were produced. Type of membership, inclusion criteria, procedures, flow and listed medicines varied greatly between the selection committees acting before and after 2012. Paradigm-changing legislation aiming at linking list compliance to public financing in 2012 produced (i) greater importance given to political and administrative stakeholders, (ii) increasing trends in number of medicines over the years, (iii) decrease in use of WHO Model List as a reference and (iv) substitution of an essential medicines list review and update process by an adoption decision output. Other issues remained unchanged. Insufficient efforts for list implementation, such as lack of physician education, presented consequences to the health system. Substantial efforts were made to produce and update the list from 2000 to 2014. However, continuous and intense health litigation disproves process outcome effectiveness.
© 2017 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Mesh:

Substances:

Year:  2017        PMID: 29117642     DOI: 10.1111/bcpt.12932

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  3 in total

1.  Strategies to Approach Medicines Litigation: An Action Research Study in Brazil.

Authors:  Fernanda Lacerda da Silva Machado; Danielle Maria de Souza Serio Dos Santos; Luciane Cruz Lopes
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

2.  Performance of a pharmaceutical services regionalization strategy policy in Minas Gerais, Brazil: Pre-post analysis from ERAF project.

Authors:  Tatiana Chama Borges Luz; Ana Karine Sarvel de Castro; Isabela Cristina Marques; Betania Barros Cota; Jèssica de Castro Alves; Michael Robert Law
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

Review 3.  National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis.

Authors:  Elizabeth F Peacocke; Sonja L Myhre; Hakan Safaralilo Foss; Unni Gopinathan
Journal:  PLoS Med       Date:  2022-03-11       Impact factor: 11.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.